A first in disease phase 2A trial of granulocyte monocyte colony stimulating factor neutralisation for axial spondyloarthritis (NAMASTE study)

Autor: Al-Mossawi, MH, Worth, C, McDonald, J, Machado, PM, Fisher, B, Chan, A, Gaffney, K, Gullick, N, Packham, J, Sengupta, R, Corn, T, Teh, J, Taylor, PC, Bowness, P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::1c17e8565afa262c93ceb80fedb05120
https://ora.ox.ac.uk/objects/uuid:3a0e92e7-0f00-4d9c-bdde-35064922fc19

Elevated type-17 cytokines are present in axial spondyloarthritis stool.

Autor: Brough I; NDORMS, Oxford University, Oxford, UK., Thompson K; Chan School of Public Health, Harvard University, Boston, MA, USA., Latore C; NDORMS, Oxford University, Oxford, UK., Penkava F; NDORMS, Oxford University, Oxford, UK., Regan C; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK., Pearson C; NDORMS, Oxford University, Oxford, UK., Shi H; NDORMS, Oxford University, Oxford, UK., Ridley A; NDORMS, Oxford University, Oxford, UK., Simone D; NDORMS, Oxford University, Oxford, UK., Lam L; NDORMS, Oxford University, Oxford, UK., Bullers S; NDORMS, Oxford University, Oxford, UK., Moussa C; NDORMS, Oxford University, Oxford, UK., Feeney R; NDORMS, Oxford University, Oxford, UK., Al-Mossawi MH; NDORMS, Oxford University, Oxford, UK., Powrie F; NDORMS, Oxford University, Oxford, UK., Young S; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK., Huttenhower C; Chan School of Public Health, Harvard University, Boston, MA, USA., Bowness P; NDORMS, Oxford University, Oxford, UK.

Publikováno v: Discovery immunology [Discov Immunol] 2024 May 04; Vol. 3 (1), pp. kyae005. Date of Electronic Publication: 2024 May 04 (Print Publication: 2024).

Peripheral CD8 ⁺ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.

Autor: Fairfax BP; MRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. benjamin.fairfax@oncology.ox.ac.uk.; Department of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. benjamin.fairfax@oncology.ox.ac.uk.; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. benjamin.fairfax@oncology.ox.ac.uk., Taylor CA; MRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Department of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Watson RA; MRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Department of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Nassiri I; MRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Department of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Danielli S; Department of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Fang H; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Mahé EA; MRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Department of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Cooper R; MRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Department of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Woodcock V; Department of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Traill Z; Department of Radiology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Al-Mossawi MH; Botnar Research Centre, NDORMS, University of Oxford, Oxford, UK., Knight JC; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Klenerman P; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK., Payne M; Department of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Middleton MR; Department of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Publikováno v: Nature medicine [Nat Med] 2020 Feb; Vol. 26 (2), pp. 193-199. Date of Electronic Publication: 2020 Feb 10.

Progress in our understanding of the pathogenesis of ankylosing spondylitis.

Autor: Simone D; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Al Mossawi MH; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Bowness P; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2018 Aug 01; Vol. 57 (suppl_6), pp. vi4-vi9.

miR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis.

Autor: Chen L; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Al-Mossawi MH; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Ridley A; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Sekine T; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Hammitzsch A; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.; Department of Nephrology, Klinikum rechts der lsar, Technical University of Munich, Munich, Germany., de Wit J; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Simone D; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Shi H; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Penkava F; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Kurowska-Stolarska M; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK., Pulyakhina I; Wellcome Trust Centre for Human Genetics, Oxford, UK., Knight JC; Nuffield Department of Medicine, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Kim TJ; Department of Rheumatology, Medical School and Hospital, Chonnam National University, Gwangju, Republic of Korea., Bowness P; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.; National Institute for Health Research Oxford Musculoskeletal Biomedical Research Unit, Oxford, UK.

Publikováno v: Annals of the rheumatic diseases [Ann Rheum Dis] 2017 Mar; Vol. 76 (3), pp. 620-625. Date of Electronic Publication: 2016 Dec 30.